Summary of COVID-19 metronidazole studies
Hide extended summaries
RCT 44 hospitalized patients with COVID-19 pneumonia showing no significant differences for oxygen saturation, length of hospital stay, or mortality with metronidazole treatment. The metronidazole group had significantly lower ESR levels on day 7.
Sep 2021, Iranian J. Pharmaceutical Research, https://doi.org/10.22037/ijpr.2021.114567.14917, https://c19p.org/kazempour
1. Kazempour et al., Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19
44 patient metronidazole late treatment RCT: 20% higher ICU admission (p=1), 25% shorter hospitalization (p=0.9), and 43% higher need for oxygen therapy (p=0.8).RCT 44 hospitalized patients with COVID-19 pneumonia showing no significant differences for oxygen saturation, length of hospital stay, or mortality with metronidazole treatment. The metronidazole group had significantly lower ESR levels on day 7.
Sep 2021, Iranian J. Pharmaceutical Research, https://doi.org/10.22037/ijpr.2021.114567.14917, https://c19p.org/kazempour
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.